Klotho Neurosciences Net Income Over Time
| KLTO Stock | 0.27 0.01 3.18% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Klotho Neurosciences Performance and Klotho Neurosciences Correlation. Will Biotechnology sector continue expanding? Could Klotho diversify its offerings? Factors like these will boost the valuation of Klotho Neurosciences. Expected growth trajectory for Klotho significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Klotho Neurosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Klotho Neurosciences is measured differently than its book value, which is the value of Klotho that is recorded on the company's balance sheet. Investors also form their own opinion of Klotho Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Klotho Neurosciences' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Klotho Neurosciences' market value can be influenced by many factors that don't directly affect Klotho Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Klotho Neurosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Klotho Neurosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Klotho Neurosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Klotho Neurosciences and related stocks such as Cadrenal Therapeutics, Rallybio Corp, and Exicure Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVKD | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (8.4 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
| NERV | (1.1 M) | (1.1 M) | (1.6 M) | (3.3 M) | (56.9 M) | (27.1 M) | (31 M) | (31.5 M) | (50.2 M) | (72.2 M) | 1.9 M | (49.9 M) | (32.1 M) | (30 M) | 1.4 M | 1.3 M | 1.4 M |
| IBIO | (1.7 M) | (5.7 M) | (6.2 M) | (3.7 M) | (6.6 M) | (9.8 M) | (14.5 M) | (16.1 M) | (17.6 M) | (16.4 M) | (23.2 M) | (50.4 M) | (29.3 M) | (24.9 M) | (18.4 M) | (16.5 M) | (17.4 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (5.6 M) | (6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
| MTVA | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (27.6 M) | (24.8 M) | (26.1 M) |
| NRXS | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3 M) | (4.8 M) | (14.6 M) | (8.2 M) | (7.4 M) | (7.8 M) |
Klotho Neurosciences and related stocks such as Cadrenal Therapeutics, Rallybio Corp, and Exicure Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Klotho Neurosciences financial statement analysis. It represents the amount of money remaining after all of Klotho Neurosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Klotho Neurosciences | KLTO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 13576 Walnut Street, |
| Exchange | NASDAQ Exchange |
null 0.2711
Check out Klotho Neurosciences Performance and Klotho Neurosciences Correlation. To learn how to invest in Klotho Stock, please use our How to Invest in Klotho Neurosciences guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Klotho Neurosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.